Vaccine trials

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 17, Issue 1, 2001, Pages 43-58

  Farrington, C P ^a   Miller, E ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

Clinical trial; Efficacy; Vaccine

Indexed keywords

VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LICENSING; MOLECULAR SIZE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

CLINICAL TRIALS; CLUSTER ANALYSIS; DOUBLE-BLIND METHOD; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; RESEARCH; RESEARCH DESIGN; VACCINES;

EID: 0035094952     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:17:1:43     Document Type: Review

References (70)

1. World Medical Association Declaration of Helsinki
2. Statistical and ethical issues in monitoring clinical trials
3. Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate
4. Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C
5. Kinetics of antibody production to group A and C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunisation of infants and children
6. Trial of a new acellular pertussis vaccine in healthy adult volunteers
7. A new vaccine against tick-borne encephalitis: Initial trial in man including a dose-response study
8. Safety and immunogenicity of a new Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine in healthy adults
9. AIDS vaccine therapy: Phase I trial
10. UK strategy for the introduction of meningococcal C conjugate vaccines
11. Human immunity to the meningococcus. I. The role of humoral antibodies
12. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines
13. Controlled trial of Haemophilus influenzae type b diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month old children, including comparison of arm versus thigh injection
14. Phase II trial of whole-cell pertussis vaccine versus an acellular vaccine
15. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants
16. Introduction to sample size determination and power analysis for clinical trials
17. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
18. Vaccination with SPf66, a chemically synthesised vaccine against Plasmodium falciparum malaria in Colombia
19. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador
20. Tropical trials and tribulations
21. Reflections on the efficacy of pertussis vaccines
22. Clinical trials of live oral rotavirus vaccines: The Finnish experience
23. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
24. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
25. The prevention of whooping-cough by vaccination: A Medical Research Council investigation
26. Quantifying misclassification bias in cohort studies of vaccine efficacy
27. Efficacy of pertussis vaccination in England
28. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial
29. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: Protective efficacy and adverse events
30. An evaluation of the 1954 poliomyelitis vaccine trials
31. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine
32. Test statistics and sample size formulae for comparative binomial trials with null hypotheses of non-zero risk difference or non-unity relative risk
33. Direct and indirect effects in vaccine efficacy and effectiveness
34. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba
35. Evaluation of group C meningococcal polysaccharide vaccine in marine recruits, San Diego, California
36. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age
37. The Gambia hepatitis intervention study
38. Simple sample size calculation for cluster-randomized trials
39. Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden
40. Child mortality after high-titre measles vaccines: Prospective study in Senegal
41. The measurement and interpretation of age-specific vaccine efficacy
42. Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: Randomization by individual versus household
43. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations
44. Vaccination against whooping cough: Relation between protection and results of laboratory tests
45. Intention-to-treat analysis: Implications for quantitative and qualitative research
46. Intention-to-treat analysis: Implications for quantitative and qualitative research
47. Randomization by group: A formal analysis
48. Role of epidemiology in vaccine policy
49. Field evaluation of vaccine efficacy
50. Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects
51. Estimation of vaccine effectiveness using the screening method
52. Confounding in studies of adverse reactions to vaccines
53. Relative incidence estimation from case series for vaccine safety evaluation
54. Case series analysis of adverse reactions to vaccines: A comparative evaluation
55. Safety assessment post-licensure
56. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999
57. Risk of aseptic meningitis after measles mumps and rubella vaccine in UK children
58. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines
59. Herd immunity: History, theory, practice
60. Efficacy of whooping-cough vaccines used in the United Kingdom before 1968
61. Meningococcal Infections 2: Field trial of group C meningococcal polysaccharide vaccine in 1969-70
62. Meningococcal conjugate vaccines: New opportunities and new challenges
63. Design considerations for AIDS trials
64. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy
65. Variation in protection by BCG: Implications of and for heterologous immunity